JP2022537047A5 - - Google Patents
Info
- Publication number
- JP2022537047A5 JP2022537047A5 JP2021575482A JP2021575482A JP2022537047A5 JP 2022537047 A5 JP2022537047 A5 JP 2022537047A5 JP 2021575482 A JP2021575482 A JP 2021575482A JP 2021575482 A JP2021575482 A JP 2021575482A JP 2022537047 A5 JP2022537047 A5 JP 2022537047A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- administration
- acceptable salt
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863406P | 2019-06-19 | 2019-06-19 | |
| US62/863,406 | 2019-06-19 | ||
| PCT/IB2020/055653 WO2020254985A1 (en) | 2019-06-19 | 2020-06-17 | Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537047A JP2022537047A (ja) | 2022-08-23 |
| JP2022537047A5 true JP2022537047A5 (https=) | 2023-06-21 |
| JP7628512B2 JP7628512B2 (ja) | 2025-02-10 |
Family
ID=71738195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575482A Active JP7628512B2 (ja) | 2019-06-19 | 2020-06-17 | ヒト免疫不全ウイルス複製の阻害剤としてのピリド［２，３－ｄ］ピリミジン誘導体 |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US12129255B2 (https=) |
| EP (1) | EP3986561B1 (https=) |
| JP (1) | JP7628512B2 (https=) |
| KR (1) | KR102932817B1 (https=) |
| CN (2) | CN114245795B (https=) |
| AR (1) | AR119174A1 (https=) |
| AU (1) | AU2020295793B2 (https=) |
| BR (1) | BR112021025655A2 (https=) |
| CL (1) | CL2021003388A1 (https=) |
| CO (1) | CO2021017479A2 (https=) |
| CR (1) | CR20210664A (https=) |
| DK (1) | DK3986561T3 (https=) |
| ES (1) | ES2974541T3 (https=) |
| FI (1) | FI3986561T3 (https=) |
| HR (1) | HRP20240501T1 (https=) |
| HU (1) | HUE065762T2 (https=) |
| IL (1) | IL288750B2 (https=) |
| LT (1) | LT3986561T (https=) |
| MA (1) | MA56526B1 (https=) |
| MD (1) | MD3986561T2 (https=) |
| MX (1) | MX2021016149A (https=) |
| MY (1) | MY206712A (https=) |
| PE (1) | PE20220510A1 (https=) |
| PH (1) | PH12021553180A1 (https=) |
| PL (1) | PL3986561T3 (https=) |
| PT (1) | PT3986561T (https=) |
| RS (1) | RS65304B1 (https=) |
| SI (1) | SI3986561T1 (https=) |
| SM (1) | SMT202400153T1 (https=) |
| TW (1) | TWI850403B (https=) |
| UA (1) | UA128967C2 (https=) |
| UY (1) | UY38755A (https=) |
| WO (1) | WO2020254985A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11541055B2 (en) | 2018-10-24 | 2023-01-03 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| BR112021025637A2 (pt) | 2019-06-19 | 2022-02-01 | Nmd Pharma As | Compostos para o tratamento de doenças neuromusculares |
| BR112021025655A2 (pt) | 2019-06-19 | 2022-02-01 | Viiv Healthcare Uk No 5 Ltd | Inibidores da replicação do vírus da imunodeficiência humana |
| MX2022003945A (es) * | 2019-10-01 | 2022-04-25 | Viiv Healthcare Co | Metodo para tratar vih con cabotegravir y rilpivirina. |
| JP7703538B2 (ja) * | 2019-12-09 | 2025-07-07 | ヴィーブ、ヘルスケア、カンパニー | カボテグラビルを含んでなる医薬組成物 |
| KR20220151655A (ko) * | 2020-03-06 | 2022-11-15 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제 |
| BR112022020933A2 (pt) * | 2020-04-15 | 2022-12-06 | Viiv Healthcare Uk No 5 Ltd | Inibidores de replicação do vírus da imunodeficiência humana |
| MX2024004551A (es) * | 2021-10-13 | 2024-06-26 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicacion del virus de inmunodeficiencia humana. |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| CN121335877A (zh) | 2023-06-15 | 2026-01-13 | Viiv保健英国第五有限公司 | 用于制备化合物的方法和中间体 |
| TW202547514A (zh) | 2024-02-05 | 2025-12-16 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1363705B9 (en) | 2001-02-02 | 2012-11-07 | Bristol-Myers Squibb Company | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US20030207910A1 (en) | 2001-02-02 | 2003-11-06 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| PL2212324T3 (pl) * | 2008-07-02 | 2014-11-28 | Avexa Ltd | Związki posiadające właściwości przeciwwirusowe |
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| ES2642265T3 (es) | 2013-01-09 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos terapéuticos para el tratamiento de infecciones virales |
| US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| TW201443037A (zh) * | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| EP3186239B1 (en) | 2014-08-29 | 2018-10-10 | Gilead Sciences, Inc. | Antiretroviral agents |
| CN119462611A (zh) | 2016-08-19 | 2025-02-18 | 吉利德科学公司 | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 |
| WO2018045150A1 (en) * | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| US11541055B2 (en) * | 2018-10-24 | 2023-01-03 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| UY38559A (es) * | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| BR112021025655A2 (pt) | 2019-06-19 | 2022-02-01 | Viiv Healthcare Uk No 5 Ltd | Inibidores da replicação do vírus da imunodeficiência humana |
-
2020
- 2020-06-17 BR BR112021025655A patent/BR112021025655A2/pt unknown
- 2020-06-17 US US17/268,107 patent/US12129255B2/en active Active
- 2020-06-17 TW TW109120334A patent/TWI850403B/zh active
- 2020-06-17 CR CR20210664A patent/CR20210664A/es unknown
- 2020-06-17 PE PE2021002114A patent/PE20220510A1/es unknown
- 2020-06-17 RS RS20240309A patent/RS65304B1/sr unknown
- 2020-06-17 DK DK20743783.1T patent/DK3986561T3/da active
- 2020-06-17 AU AU2020295793A patent/AU2020295793B2/en active Active
- 2020-06-17 IL IL288750A patent/IL288750B2/en unknown
- 2020-06-17 CN CN202080052305.0A patent/CN114245795B/zh active Active
- 2020-06-17 SM SM20240153T patent/SMT202400153T1/it unknown
- 2020-06-17 PH PH1/2021/553180A patent/PH12021553180A1/en unknown
- 2020-06-17 FI FIEP20743783.1T patent/FI3986561T3/fi active
- 2020-06-17 WO PCT/IB2020/055653 patent/WO2020254985A1/en not_active Ceased
- 2020-06-17 PL PL20743783.1T patent/PL3986561T3/pl unknown
- 2020-06-17 HU HUE20743783A patent/HUE065762T2/hu unknown
- 2020-06-17 PT PT207437831T patent/PT3986561T/pt unknown
- 2020-06-17 EP EP20743783.1A patent/EP3986561B1/en active Active
- 2020-06-17 ES ES20743783T patent/ES2974541T3/es active Active
- 2020-06-17 HR HRP20240501TT patent/HRP20240501T1/hr unknown
- 2020-06-17 UA UAA202200207A patent/UA128967C2/uk unknown
- 2020-06-17 MX MX2021016149A patent/MX2021016149A/es unknown
- 2020-06-17 SI SI202030385T patent/SI3986561T1/sl unknown
- 2020-06-17 AR ARP200101700A patent/AR119174A1/es unknown
- 2020-06-17 UY UY0001038755A patent/UY38755A/es unknown
- 2020-06-17 MY MYPI2021007563A patent/MY206712A/en unknown
- 2020-06-17 JP JP2021575482A patent/JP7628512B2/ja active Active
- 2020-06-17 MD MDE20220479T patent/MD3986561T2/ro unknown
- 2020-06-17 LT LTEPPCT/IB2020/055653T patent/LT3986561T/lt unknown
- 2020-06-17 KR KR1020227001501A patent/KR102932817B1/ko active Active
- 2020-06-17 MA MA56526A patent/MA56526B1/fr unknown
- 2020-06-17 CN CN202410979514.XA patent/CN119039288A/zh active Pending
-
2021
- 2021-12-17 CL CL2021003388A patent/CL2021003388A1/es unknown
- 2021-12-20 CO CONC2021/0017479A patent/CO2021017479A2/es unknown
-
2024
- 2024-09-18 US US18/888,497 patent/US20250019383A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022537047A5 (https=) | ||
| JP2022531251A5 (https=) | ||
| JP7330312B2 (ja) | Ｈｉｖを治療するためのトール様受容体の調節因子 | |
| JP2022191257A5 (https=) | ||
| JP2024516371A5 (https=) | ||
| HRP20240501T1 (hr) | Derivati pirido[2,3-d]pirimidina kao inhibitori replikacije virusa humane imunodeficijencije | |
| JP2021063088A5 (https=) | ||
| JP2021100937A5 (https=) | ||
| JP2018188483A5 (https=) | ||
| JP2022523726A5 (https=) | ||
| JP2020097577A5 (https=) | ||
| JP2024540183A5 (https=) | ||
| JP2015038149A5 (https=) | ||
| JP2016516773A5 (https=) | ||
| JP2024512425A5 (https=) | ||
| JP2024507788A5 (https=) | ||
| JP2024520132A5 (https=) | ||
| JP2025520237A5 (ja) | 哺乳動物の非結核性マイコバクテリア感染症治療薬 | |
| JP2020536098A5 (https=) | ||
| JP2023531930A5 (https=) | ||
| JP2024535596A5 (https=) | ||
| JP2002533470A5 (https=) | ||
| JP2005507944A5 (https=) | ||
| AU2018239257B2 (en) | HIV post-exposure prophylaxis | |
| JP2022533011A5 (https=) |